Literature DB >> 25085360

Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma.

Annamaria Brioli1, Beatrice Anna Zannetti1, Elena Zamagni1, Paola Tacchetti1, Lucia Pantani1, Katia Mancuso1, Annalisa Pezzi1, Serena Rocchi1, Michele Cavo2.   

Abstract

Entities:  

Keywords:  multiple myeloma; peripheral neuropathy; subcutaneous bortezomib

Mesh：

Year:  2014        PMID： 25085360      PMCID： PMC4222458          DOI： 10.3324/haematol.2014.110221

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.

Authors:  Paola Tacchetti; Carolina Terragna; Monica Galli; Elena Zamagni; Maria Teresa Petrucci; Annalisa Pezzi; Vittorio Montefusco; Marina Martello; Patrizia Tosi; Luca Baldini; Jacopo Peccatori; Miriana Ruggieri; Lucia Pantani; Antonio Lazzaro; Francesca Elice; Serena Rocchi; Alessandro Gozzetti; Guido Cavaletti; Antonio Palumbo; Michele Cavo
Journal:  Am J Hematol       Date:  2014-09-17       Impact factor: 10.047

2.  Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

Authors:  Paul G Richardson; Hannah Briemberg; Sundar Jagannath; Patrick Y Wen; Bart Barlogie; James Berenson; Seema Singhal; David S Siegel; David Irwin; Michael Schuster; Gordan Srkalovic; Raymond Alexanian; S Vincent Rajkumar; Steven Limentani; Melissa Alsina; Robert Z Orlowski; Kevin Najarian; Dixie Esseltine; Kenneth C Anderson; Anthony A Amato
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

3.  Progression of paclitaxel-induced neuropathy following discontinuation of treatment.

Authors:  M J van den Bent; V J van Raaij-van den Aarssen; J Verweij; P A Doorn; P A Sillevis Smitt
Journal:  Muscle Nerve       Date:  1997-06       Impact factor: 3.217

4.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Authors:  Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila El Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Edo Vellenga; Annemiek Broyl; Igor W Blau; Katja C Weisel; Shulamiet Wittebol; Gerard M J Bos; Marian Stevens-Kroef; Christof Scheid; Michael Pfreundschuh; Dirk Hose; Anna Jauch; Helgi van der Velde; Reinier Raymakers; Martijn R Schaafsma; Marie-Jose Kersten; Marinus van Marwijk-Kooy; Ulrich Duehrsen; Walter Lindemann; Pierre W Wijermans; Henk M Lokhorst; Hartmut M Goldschmidt
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

5.  Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.

Authors:  Anne Lok; Julie Mocquard; Jessie Bourcier; Laurence Redelsperger; Antoine Bonnet; Cecile Chauvin; Patrick Thomaré; Beatrice Mahé; Cyrille Touzeau; Philippe Moreau
Journal:  Haematologica       Date:  2014-02-14       Impact factor: 9.941

6.  Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.

Authors:  Gunjan Shah; Esha Kaul; Shelly Fallo; Furha Cossor; Hedy Smith; Kellie Sprague; Andreas Klein; Kenneth Miller; Raymond Comenzo
Journal:  Clin Ther       Date:  2013-09-26       Impact factor: 3.393

7.  Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Authors:  Philippe Moreau; Herve Avet-Loiseau; Thierry Facon; Michel Attal; Mourad Tiab; Cyrille Hulin; Chantal Doyen; Laurent Garderet; Edouard Randriamalala; Carla Araujo; Gérard Lepeu; Gerald Marit; Denis Caillot; Martine Escoffre; Bruno Lioure; Lotfi Benboubker; Brigitte Pégourié; Brigitte Kolb; Anne Marie Stoppa; Jean-Gabriel Fuzibet; Olivier Decaux; Mamoun Dib; Christian Berthou; Carine Chaleteix; Catherine Sebban; Catherine Traullé; Jean Fontan; Marc Wetterwald; Pascal Lenain; Claire Mathiot; Jean-Luc Harousseau
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

8.  Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

Authors:  Heinz Ludwig; Luisa Viterbo; Richard Greil; Tamas Masszi; Ivan Spicka; Ofer Shpilberg; Roman Hajek; Anna Dmoszynska; Bruno Paiva; María-Belén Vidriales; Graca Esteves; Anne Marie Stoppa; Don Robinson; Deborah Ricci; Andrew Cakana; Christopher Enny; Huaibao Feng; Helgi van de Velde; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

Review 9.  Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

Authors:  Andreas A Argyriou; Gregoris Iconomou; Haralabos P Kalofonos
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

10.  Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.

Authors:  W Lamm; B Drach-Schauer; S Eder; J Drach
Journal:  Oncology       Date:  2013-09-27       Impact factor: 2.935
View more
  2 in total

1.  Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

Authors:  Maximilian Merz; Hans Salwender; Mathias Haenel; Elias K Mai; Uta Bertsch; Christina Kunz; Thomas Hielscher; Igor W Blau; Christof Scheid; Dirk Hose; Anja Seckinger; Anna Jauch; Jens Hillengass; Marc S Raab; Baerbel Schurich; Markus Munder; Ingo G H Schmidt-Wolf; Christian Gerecke; Hans-Walter Lindemann; Matthias Zeis; Katja Weisel; Jan Duerig; Hartmut Goldschmidt
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

2.  Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Authors:  E K Mai; U Bertsch; J Dürig; C Kunz; M Haenel; I W Blau; M Munder; A Jauch; B Schurich; T Hielscher; M Merz; B Huegle-Doerr; A Seckinger; D Hose; J Hillengass; M S Raab; K Neben; H-W Lindemann; M Zeis; C Gerecke; I G H Schmidt-Wolf; K Weisel; C Scheid; H Salwender; H Goldschmidt
Journal:  Leukemia       Date:  2015-03-19       Impact factor: 11.528
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.